Skip to content

Australian-invented drug technology used for treatment of anxiety disorders significantly reduces stress hormone response: Phase 2a clinical trial results

By Gold Cross - November 17, 2023

Clinical trial
This article is only available to ITK members and is restricted for Pharmacists. Please or Register as a Pharmacist to read the content.
Share this article:
Article tags

Articles you might be interested in

, ,

Snow Centre for Immune Health to revolutionise global immunology research

Gold Cross | November 21, 2023
Pharmacist Only
,

LTR Pharma, Brisbane innovator, set for ASX debut with groundbreaking 10-minute erectile dysfunction drug

Gold Cross | November 20, 2023
, ,

From sceptic to super user: How VR boosts workforce morale and enhances dementia care

Gold Cross | November 20, 2023
Pharmacist Only
,

Australian-invented drug technology used for treatment of anxiety disorders significantly reduces stress hormone response: Phase 2a clinical trial results

Gold Cross | November 17, 2023
BD Rowa automation gives you back 6 hours in your day

Latest Posts

We stand ready to help more patients
Gold Cross | November 29, 2023
New Board members at National Rural Health Alliance
Gold Cross | November 29, 2023
Premier Chris Minns expands pharmacy trial as 6000 women bypass GPs for over-the-counter consults
Gold Cross | November 28, 2023

Featured Posts

Gold Cross parts ways with Kings Transport
Gold Cross | November 28, 2023
Cost of living now costing our health
Gold Cross | November 21, 2023
Pharmacy firsts
Gold Cross | November 17, 2023

Tags

Scroll To Top